{"id":119044,"date":"2025-05-14T14:34:33","date_gmt":"2025-05-14T22:34:33","guid":{"rendered":"https:\/\/xira.com\/p\/2025\/05\/14\/pharma-company-incyte-settles-novartis-royalties-dispute-for-280-million-sec-records-show\/"},"modified":"2025-05-14T14:34:33","modified_gmt":"2025-05-14T22:34:33","slug":"pharma-company-incyte-settles-novartis-royalties-dispute-for-280-million-sec-records-show","status":"publish","type":"post","link":"https:\/\/xira.com\/p\/2025\/05\/14\/pharma-company-incyte-settles-novartis-royalties-dispute-for-280-million-sec-records-show\/","title":{"rendered":"Pharma Company Incyte Settles Novartis Royalties Dispute for $280 Million, SEC Records Show"},"content":{"rendered":"<p>In a SEC filing dated Sunday, Incyte, which is both incorporated and headquartered in Delaware, indicated the payment represents roughly five years of disputed royalty payments linked to the drug Jakafi. Quinn Emanuel Urquhart &amp; Sullivan and Paul Hastings represented Wilmington, Delaware-based Incyte.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" align=\"left\" border=\"0\" height=\"1\" width=\"1\" alt=\"\" hspace=\"0\" src=\"https:\/\/feeds.feedblitz.com\/~\/i\/918302603\/0\/law\/legal-news\" title=\"\"><\/p>\n<div><a href=\"https:\/\/feeds.feedblitz.com\/_\/2\/918302603\/law\/legal-news\" rel=\"nofollow noopener\" target=\"_blank\"><img data-recalc-dims=\"1\" width=\"1080\" decoding=\"async\" height=\"20\" src=\"https:\/\/i0.wp.com\/assets.feedblitz.com\/i\/fbshare20.png?fit=1080%2C20&#038;ssl=1\" alt=\"\" title=\"\"><\/a>\u00a0<a href=\"https:\/\/feeds.feedblitz.com\/_\/28\/918302603\/law\/legal-news\" rel=\"nofollow noopener\" target=\"_blank\"><img data-recalc-dims=\"1\" width=\"1080\" decoding=\"async\" height=\"20\" src=\"https:\/\/i0.wp.com\/assets.feedblitz.com\/i\/fblike20.png?fit=1080%2C20&#038;ssl=1\" alt=\"\" title=\"\"><\/a>\u00a0<a href=\"https:\/\/feeds.feedblitz.com\/_\/29\/918302603\/law\/legal-news,\" rel=\"nofollow noopener\" target=\"_blank\"><img data-recalc-dims=\"1\" width=\"1080\" decoding=\"async\" height=\"20\" src=\"https:\/\/i0.wp.com\/assets.feedblitz.com\/i\/pinterest20.png?fit=1080%2C20&#038;ssl=1\" alt=\"\" title=\"\"><\/a>\u00a0<a href=\"https:\/\/feeds.feedblitz.com\/_\/12\/918302603\/law\/legal-news\" rel=\"nofollow noopener\" target=\"_blank\"><img data-recalc-dims=\"1\" width=\"1080\" decoding=\"async\" height=\"20\" src=\"https:\/\/i0.wp.com\/assets.feedblitz.com\/i\/stumble20.png?fit=1080%2C20&#038;ssl=1\" alt=\"\" title=\"\"><\/a>\u00a0<a href=\"https:\/\/feeds.feedblitz.com\/_\/24\/918302603\/law\/legal-news\" rel=\"nofollow noopener\" target=\"_blank\"><img data-recalc-dims=\"1\" width=\"1080\" decoding=\"async\" height=\"20\" src=\"https:\/\/i0.wp.com\/assets.feedblitz.com\/i\/x.png?fit=1080%2C20&#038;ssl=1\" alt=\"\" title=\"\"><\/a>\u00a0<a href=\"https:\/\/feeds.feedblitz.com\/_\/20\/918302603\/law\/legal-news\" rel=\"nofollow noopener\" target=\"_blank\"><img data-recalc-dims=\"1\" width=\"1080\" decoding=\"async\" height=\"20\" src=\"https:\/\/i0.wp.com\/assets.feedblitz.com\/i\/rss20.png?fit=1080%2C20&#038;ssl=1\" alt=\"\" title=\"\"><\/a>\u00a0\u00a0<\/div>\n<p>In a SEC filing dated Sunday, Incyte, which is both incorporated and headquartered in Delaware, indicated the payment represents roughly five years of disputed royalty payments linked to the drug Jakafi. Quinn Emanuel Urquhart &amp; Sullivan and Paul Hastings represented Wilmington, Delaware-based Incyte.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" align=\"left\" border=\"0\" height=\"1\" width=\"1\" alt=\"\" hspace=\"0\" src=\"https:\/\/feeds.feedblitz.com\/~\/i\/918302603\/0\/law\/legal-news\" title=\"\"><\/p>\n<div><a href=\"https:\/\/feeds.feedblitz.com\/_\/2\/918302603\/law\/legal-news\" rel=\"nofollow noopener\" target=\"_blank\"><img data-recalc-dims=\"1\" width=\"1080\" decoding=\"async\" height=\"20\" src=\"https:\/\/i0.wp.com\/assets.feedblitz.com\/i\/fbshare20.png?fit=1080%2C20&#038;ssl=1\" alt=\"\" title=\"\"><\/a>\u00a0<a href=\"https:\/\/feeds.feedblitz.com\/_\/28\/918302603\/law\/legal-news\" rel=\"nofollow noopener\" target=\"_blank\"><img data-recalc-dims=\"1\" width=\"1080\" decoding=\"async\" height=\"20\" src=\"https:\/\/i0.wp.com\/assets.feedblitz.com\/i\/fblike20.png?fit=1080%2C20&#038;ssl=1\" alt=\"\" title=\"\"><\/a>\u00a0<a href=\"https:\/\/feeds.feedblitz.com\/_\/29\/918302603\/law\/legal-news,\" rel=\"nofollow noopener\" target=\"_blank\"><img data-recalc-dims=\"1\" width=\"1080\" decoding=\"async\" height=\"20\" src=\"https:\/\/i0.wp.com\/assets.feedblitz.com\/i\/pinterest20.png?fit=1080%2C20&#038;ssl=1\" alt=\"\" title=\"\"><\/a>\u00a0<a href=\"https:\/\/feeds.feedblitz.com\/_\/12\/918302603\/law\/legal-news\" rel=\"nofollow noopener\" target=\"_blank\"><img data-recalc-dims=\"1\" width=\"1080\" decoding=\"async\" height=\"20\" src=\"https:\/\/i0.wp.com\/assets.feedblitz.com\/i\/stumble20.png?fit=1080%2C20&#038;ssl=1\" alt=\"\" title=\"\"><\/a>\u00a0<a href=\"https:\/\/feeds.feedblitz.com\/_\/24\/918302603\/law\/legal-news\" rel=\"nofollow noopener\" target=\"_blank\"><img data-recalc-dims=\"1\" width=\"1080\" decoding=\"async\" height=\"20\" src=\"https:\/\/i0.wp.com\/assets.feedblitz.com\/i\/x.png?fit=1080%2C20&#038;ssl=1\" alt=\"\" title=\"\"><\/a>\u00a0<a href=\"https:\/\/feeds.feedblitz.com\/_\/20\/918302603\/law\/legal-news\" rel=\"nofollow noopener\" target=\"_blank\"><img data-recalc-dims=\"1\" width=\"1080\" decoding=\"async\" height=\"20\" src=\"https:\/\/i0.wp.com\/assets.feedblitz.com\/i\/rss20.png?fit=1080%2C20&#038;ssl=1\" alt=\"\" title=\"\"><\/a>\u00a0\u00a0<\/div>\n","protected":false},"excerpt":{"rendered":"<p>In a SEC filing dated Sunday, Incyte, which is both incorporated and headquartered in Delaware, indicated the payment represents roughly five years of disputed royalty payments linked to the drug Jakafi. Quinn Emanuel Urquhart &amp; Sullivan and Paul Hastings represented Wilmington, Delaware-based Incyte. \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 In a SEC filing dated Sunday, Incyte, which is both incorporated [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":119045,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[23],"tags":[],"class_list":["post-119044","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-law-com"],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/xira.com\/p\/wp-content\/uploads\/2025\/05\/legal-news-RbI2h9.jpeg?fit=767%2C633&ssl=1","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/xira.com\/p\/wp-json\/wp\/v2\/posts\/119044","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/xira.com\/p\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/xira.com\/p\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/xira.com\/p\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/xira.com\/p\/wp-json\/wp\/v2\/comments?post=119044"}],"version-history":[{"count":0,"href":"https:\/\/xira.com\/p\/wp-json\/wp\/v2\/posts\/119044\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/xira.com\/p\/wp-json\/wp\/v2\/media\/119045"}],"wp:attachment":[{"href":"https:\/\/xira.com\/p\/wp-json\/wp\/v2\/media?parent=119044"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/xira.com\/p\/wp-json\/wp\/v2\/categories?post=119044"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/xira.com\/p\/wp-json\/wp\/v2\/tags?post=119044"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}